secwatch.observer — SEC 8-K summary
======================================

Issuer:     FILANA THERAPEUTICS, INC. (FLNA)
CIK:        0001069530
Form:       8-K
Filed at:   2025-04-21T23:59:59+00:00
Accession:  0001437749-25-012540
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cassava Sciences CMO retiring; new COO/Legal and SVP Clinical Dev appointed
---------------------------------------------------------------------------

- CMO Dr. James Kupiec retiring effective May 9, 2025.
- R. Christopher Cook promoted to COO & Legal Officer from SVP/GC; base salary raised to $475,000.
- Dr. Jack Moore appointed SVP Clinical Development effective April 28, 2025.
- CFO Eric Schoen's employment agreement amended and restated; base salary unchanged.
- Company advancing simufilam for TSC-related epilepsy after Alzheimer's program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069530/000143774925012540/0001437749-25-012540-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069530/000143774925012540/sava20250418_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-012540

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer